

Edgar Filing: QUEST DIAGNOSTICS INC - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 Entry into a Material Definitive Agreement

On March 12, 2019, Quest Diagnostics Incorporated (the “Company”) issued \$500,000,000 aggregate principal amount of 4.200% Senior Notes due 2029 (the “Notes”).

The Company will pay interest on the Notes on June 30 and December 30 of each year, beginning on June 30, 2019.

The Notes will mature on June 30, 2029. The Notes will be the senior unsecured obligations of the Company and will rank equally with the Company’s other and future senior unsecured obligations. The Notes will not be entitled to the benefit of any sinking fund.

The Notes were issued pursuant to an indenture dated as of June 27, 2001 among the Company, the guarantors (as defined therein) and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented from time to time, and as further supplemented by a nineteenth supplemental indenture dated as of March 12, 2019 between the Company and the Trustee (collectively, the “Indenture”). The Indenture contains covenants that, among other things, will limit the ability of the Company and any subsidiary guarantors to create certain liens; enter into certain sale and leaseback transactions; consolidate, merge or transfer all or substantially all of the Company’s assets and the assets of the Company’s subsidiaries on a consolidated basis; incur indebtedness of non-guarantor subsidiaries; and make restricted payments to certain non-guarantor subsidiaries. The Indenture provides for customary events of default. Upon a change of control triggering event (as defined in the Indenture), the Company will be required to make an offer to purchase the Notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to, but excluding, the date of repurchase.

The foregoing description of the Indenture does not purport to be complete and is qualified in its entirety by reference to the text of the applicable agreements, each of which is included as an exhibit to this Current Report on Form 8-K and incorporated by reference herein.

A copy of the opinion of Shearman & Sterling LLP, counsel to the Company, relating to the legality of the Notes is filed as Exhibit 5.1 to this Report.

Item 8.01 Other Events

On March 7, 2019, the Company issued a press release announcing the pricing of a public offering of \$500 million aggregate principal amount of its 4.200% senior notes due 2029 under the Company’s shelf registration statement. A copy of the press release, dated March 7, 2019, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.

In connection with the offering of the Notes, on March 7, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC on behalf of themselves and the other underwriters named therein. The Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated by reference into this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

Exhibit Description

- | | |
|-------------|---|
| <u>1.1*</u> | <u>Underwriting Agreement, dated March 7, 2019</u> |
| <u>4.1</u> | <u>Indenture dated as of June 27, 2001, among the Company, the Subsidiary Guarantors and the Trustee (filed as an Exhibit to the Company’s current report on Form 8-K (Date of Report: June 27, 2001) and incorporated herein by reference)</u> |
| <u>4.2*</u> | <u>Nineteenth Supplemental Indenture, dated as of March 12, 2019, between the Company and the Trustee</u> |

Edgar Filing: QUEST DIAGNOSTICS INC - Form 8-K

- 4.3* Form of the Company's 4.200% Senior Note due 2029 (incorporated by reference from Exhibit A to Exhibit 4.2 hereof)
 - 5.1* Opinion of Shearman & Sterling LLP, counsel to the Company
 - 23.1* Consent of Shearman & Sterling LLP (included in Exhibit 5.1)
 - 99.1* Press Release issued by the Company, dated March 7, 2019, announcing pricing of notes
- * Filed herewith.
-

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

March 12, 2019

QUEST DIAGNOSTICS
INCORPORATED

By /s/ William J. O'Shaughnessy, Jr.
William J. O'Shaughnessy, Jr.
Deputy General Counsel and Secretary
